Review Article
Immunogenicity of biosimilar monoclonal antibodies
Abstract: Biosimilar monoclonal antibodies (mAbs) are making their way onto the drug market. Because these are complex molecules in terms of structure and function, assessing similarity between originator and biosimilar… Read More »
Understanding the components of pharmaceutical expenditure—overview of pharmaceutical policies influencing expenditure across European countries
Author(s): 1 Sabine Vogler, PhD, 2 Nina Zimmermann, MA, Claudia Habl
Page: 178-87
Aim: To explain the components of pharmaceutical expenditure and illustrate the strengths and limitations of this indicator. In particular, we explore policies applied in European countries that affect the price… Read More »
Safety and toxicity of biosimilars—EU versus US regulation
Author(s): 1 Tobias Blank, PhD, Angela Vogt-Eisele, PhD, Professor Marietta Kaszkin-Bettag, PhD, Tilo Netzer, PhD, Wolfram Hildebrandt, MSc, MA
Page: 144-50
Author byline as per print journal: Tobias Blank, PhD, Tilo Netzer, PhD, Wolfram Hildebrandt, MSc, MA, Angela Vogt-Eisele, PhD, Professor Marietta Kaszkin-Bettag, PhD Background: As patents for biological drugs begin… Read More »
Steps to ensure adequate supply of biological medicines: considerations for the healthcare provider
Author byline as per print journal: Andrew Mica, MBA, Martha Mutomba, PhD, Larry Green, PharmD Introduction: When drug shortages occur, healthcare providers (HCPs) often must ration drugs, cancel or delay… Read More »
Pharmacokinetics of antimicrobials in obese children
Author(s): 1 Mario R Sampson, PharmD, et al.
Page: 76-81
Author byline as per print journal: Mario R Sampson, PharmD; Michael Cohen-Wolkowiez, MD, PhD; Professor Daniel Kelly Benjamin Jr, MD, MPH, PhD; Edmund V Capparelli, PharmD; Kevin M Watt, MD… Read More »
Biosimilars in the European market
Author(s): Antonio Olry de Labry, PhD, Emmanuel Giménez, BSc, Leandro Lindner, BSc, Leticia García, BSc, Professor Jaime Espín, PhD, Professor Joan Rovira, PhD
Page: 30-5
Author byline as per print journal: Professor Joan Rovira, PhD; Leandro Lindner, BSc; Emmanuel Giménez, BSc; Professor Jaime Espín, PhD; Antonio Olry de Labry, PhD; Leticia García, BSc Introduction and… Read More »
Current status of biopharmaceuticals in Iran’s pharmaceutical market
Author(s): Professor Abdol Majid Cheraghali, PharmaD, PhD
Page: 26-9
Abstract: The clinical importance of biopharmaceuticals for the management of life threatening diseases is increasing but costs have become a major obstacle to the administration of these medicines, especially in… Read More »
Assessing biosimilarity and interchangeability of biosimilar products under the Biologics Price Competition and Innovation Act
Page: 20-5
Author byline as per print journal: Professor Shein-Chung Chow, PhD, Christine Ju, MSc Abstract: Biological (large molecule) drug products are made via living systems and are complex and variable in nature.… Read More »
Reference pricing systems in Europe: characteristics and consequences
Author(s): Pieter Dylst, PharmD, Professor Arnold G Vulto, PharmD, PhD, FCP, Steven Simoens, MSc, PhD
Page: 127-131
Author byline as per print journal: Pieter Dylst, PharmD; Professor Steven Simoens, MSc, PhD; Professor Arnold G Vulto, PharmD, PhD Introduction: A reference pricing system is a system that establishes a common reimbursement level… Read More »
Payers endorse generics to enhance prescribing efficiency: impact and future implications, a case history approach
Author byline as per print journal: Brian Godman1,2,3, BSc, PhD; Mohammed Abuelkhair4, PharmD; Agnes Vitry5, PharmD, PhD; Shajahan Abdu4, MD; Marion Bennie6,7, MSc; Iain Bishop7, BSc; Sahar Fahmy4, PhD; Kristina Garuoliene8,… Read More »